DOCTR Resource Center Planning

 描述（由申请人提供）：加州大学洛杉矶分校，斯坦福大学和全国各地的研究人员的许多基本发现导致了干细胞，生长因子，药物输送载体和生物活性支架材料的新技术。尽管取得了巨大的进步，但很少有发现能够发展成为FDA批准的组织工程产品。此外，很少有生物测定和动物模型可用于可靠验证组织再生产品的安全性和有效性。这种差异是由于臭名昭著的“死亡之谷”将惊人的科学与患者的利益分开。跨学科的UCLA-Stanford Dental Oral Craniofacial Tissue Regeneration Center（UCLA-Stanford DOCTRC）是一个公私合营的财团，其主要使命是提供科学、技术、监管、财务和管理资源，以促进牙科口腔颅面组织再生产品的成本效益过渡和及时开发。在第1阶段规划阶段，将举行4次季度会议和9次月度工作会议，以1）开发组织结构，利用现有资源，确定未满足的资源需求; 2）开发跨学科翻译项目团队，以构建领先和管道DOC组织再生产品。

 DESCRIPTION (provided by applicant): Many basic discoveries made by researchers at UCLA, Stanford, and across the nation have led to novel technologies in stem cells, growth factors, drug delivery carriers, and bioactive scaffolding materials. Despite this tremendous progress, very few discoveries manage to advance to FDA approved tissue engineering products. Furthermore, few bioassays and animal models are available for reliable validation of safety and efficacy for the tissue regeneration products. This discrepancy is due to the infamous "Valley of Death" that separates amazing science from patient benefits. The interdisciplinary UCLA-Stanford Dental Oral Craniofacial Tissue Regeneration Center (UCLA-Stanford DOCTRC) is a public-private consortium with the primary mission of providing scientific, technical, regulatory, financial, and management resources to promote cost-effective transition and timely development of dental oral craniofacial tissue regeneration products. During this Stage 1 planning phase, 4 quarterly conferences and und 9 monthly working meetings will be held to 1) develop organizational structure, leverage existing resources, identify unmet resource needs; and 2) Develop Interdisciplinary Translational Project teams to build lead and pipeline DOC tissue regeneration products.